{
  "image_filename": "table_p4_det_3_003.png",
  "image_path": "Treanor_et_al.__2011_/extracted/figures/table_p4_det_3_003.png",
  "image_type": "Table",
  "page_number": 4,
  "block_id": "det_3_003",
  "claim_id": "claim_002",
  "claim": "Cell- and egg-based flu vaccines have the potential to develop mutations during production, which may reduce their effectiveness.",
  "supports_claim": false,
  "explanation": "A table presenting pre- and post-vaccination (day 0 and day 28) geometric mean antibody titers (with 95% CIs) and percentage response rates to three influenza vaccine antigens (A/Solomon Island/3/2006 H1N1, A/Wisconsin/67/2005 H3N2, B/Malaysia/2506/2004) across four groups: placebo, FluBlok, FluBlok PV, and FluBlok NPV. does not support the claim: the table provides immunogenicity and response rate data but contains no information on vaccine production methods, mutations arising during production, or their impact on effectiveness. Note: The snippet is clear and focused solely on antibody titers and response rates; no details on production-induced mutations are visible.",
  "model_used": "o4-mini",
  "detailed_analysis": {
    "supports_claim": false,
    "image_description": "A table presenting pre- and post-vaccination (day 0 and day 28) geometric mean antibody titers (with 95% CIs) and percentage response rates to three influenza vaccine antigens (A/Solomon Island/3/2006 H1N1, A/Wisconsin/67/2005 H3N2, B/Malaysia/2506/2004) across four groups: placebo, FluBlok, FluBlok PV, and FluBlok NPV.",
    "evidence_found": null,
    "reasoning": "does not support the claim: the table provides immunogenicity and response rate data but contains no information on vaccine production methods, mutations arising during production, or their impact on effectiveness.",
    "confidence_notes": "The snippet is clear and focused solely on antibody titers and response rates; no details on production-induced mutations are visible."
  }
}